Update on hypertrophic cardiomyopathy and a guide to the guidelines. (Q30245043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

review article

1 reference

title

Update on hypertrophic cardiomyopathy and a guide to the guidelines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

hypertrophic cardiomyopathy

24 March 2020

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Srijita Sen-Chowdhry

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

Daniel Jacoby

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

William J McKenna

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

language of work or name

English

0 references

publication date

29 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

Nature Reviews Cardiology

24 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

page(s)

651-675

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies

24 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Standing on the Shoulders of Giants: J.A.P. Paré and the Birth of Cardiovascular Genetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Asymetric septal hypertrophy in childhood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical course of hypertrophic cardiomyopathy in a regional United States cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the Euro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ameri

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Myotonic dystrophy: time for evidence-based therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Cardiac abnormalities in acromegaly. Pathophysiology and implications for management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Update on role of agalsidase alfa in management of Fabry disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Evolving landscape in the management of transthyretin amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Characterization of the cardiomyopathy in infants of diabetic mothers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Myocardial disarray in Noonan syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Genetics of restrictive cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Insights and challenges in hypertrophic cardiomyopathy, 2012.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Right ventricular involvement in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Right ventricular remodeling, its correlates, and its clinical impact in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Myocardial T1 mapping: techniques and potential applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

T1 Mapping by CMR Imaging: From Histological Validation to Clinical Implication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

The Incremental Value of Magnetic Resonance Imaging for Identification of Apical Pouch in Patients with Apical Variant of Hypertrophic Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic Cardiomyopathy in Childhood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Shared genetic causes of cardiac hypertrophy in children and adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

What is the best approach for the assessment of left atrial size? Comparison of various unidimensional and two-dimensional parameters with three-dimensional echocardiographically determined left atrial volume

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Regional heterogeneity of function in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A new method for quantification of left ventricular systolic function using a corrected ejection fraction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Reflections of inflections in hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy--the lobster claw abnormality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy: the search for obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Abnormal left ventricular intracavitary flow acceleration in patients undergoing aortic valve replacement for aortic stenosis. A marker for high postoperative morbidity and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Cardiac structural and sarcomere genes associated with cardiomyopathy exhibit marked intolerance of genetic variation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Double or compound sarcomere mutations in hypertrophic cardiomyopathy: A potential link to sudden death in the absence of conventional risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

New perspectives on the prevalence of hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiac troponin T gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A novel Myosin essential light chain mutation causes hypertrophic cardiomyopathy with late onset and low expressivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Diastolic abnormalities in normal phenotype hypertrophic cardiomyopathy gene carriers: a study using speckle tracking echocardiography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Abnormal cardiac formation in hypertrophic cardiomyopathy: fractal analysis of trabeculae and preclinical gene expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Deep basal inferoseptal crypts occur more commonly in patients with hypertrophic cardiomyopathy due to disease-causing myofilament mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence of inferobasal myocardial crypts among patients referred for cardiovascular magnetic resonance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Myocardial clefts, crypts, or crevices: once again, you see only what you look for

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Left ventricular outflow tract obstruction as a primary phenotypic expression of hypertrophic cardiomyopathy in mutation carriers without hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Isolated hypertrophy of the basal ventricular septum: Characteristics of patients with and without outflow tract obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

31 March 2020

Basal septal hypertrophy

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Cardiac adaptation to exercise in adolescent athletes of African ethnicity: an emergent elite athletic population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic Cardiomyopathy-One Case per Year?: A Clarion Call to Do What Is Right

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Short and medium term outcomes of surgery for patients with hypertrophic obstructive cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Myectomy and mitral repair through the left atrium in hypertrophic obstructive cardiomyopathy: the preferred approach for contemporary surgical candidates?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Biventricular pacing in hypertrophic obstructive cardiomyopathy: A pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Effect of cardiac resynchronization on gradient reduction in patients with obstructive hypertrophic cardiomyopathy: preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Can septal myectomy prevent sudden cardiac death in hypertrophic obstructive cardiomyopathy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Percutaneous mitral valve repair and replacement: a new landmark for structural heart interventions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Robot-assisted septal myectomy for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Minimally Invasive Trans-Mitral Septal Myectomy to Treat Hypertrophic Obstructive Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

In defense of antimicrobial prophylaxis for prevention of infective endocarditis in patients with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy patients: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2 fluxes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Single-molecule dual-beam optical trap analysis of protein structure and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Familial hypertrophic cardiomyopathy: functional variance among individual cardiomyocytes as a trigger of FHC-phenotype development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Innovative approaches to anti-arrhythmic drug therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2016.140

Penetrance of familial hypertrophic cardiomyopathy

31 March 2020

1 reference

12 December 2020

Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy

1 reference

12 December 2020

Keynote Lecture-Transmitral hypertrophic obstructive cardiomyopathy (HOCM) repair

1 reference

12 December 2020

Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes

1 reference

12 December 2020

Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy

1 reference

12 December 2020

Biventricular / left ventricular pacing in hypertrophic obstructive cardiomyopathy: an overview

1 reference

12 December 2020

From Teare to the present day: a fifty year odyssey in hypertrophic cardiomyopathy, a paradigm for the logic of the discovery process.

1 reference

12 December 2020

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

1 reference

12 December 2020

10.1038/NRCARDIO.2016.140

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27681577 AND SRC:MED&resulttype=core&format=json

24 March 2020

1 reference